Comprehensive coverage on the latest pharmaceutical regulatory update and industry activities in China.
China Releases Draft List of Second Batch of Encouraged Generic Medicines On Dec. 30, 2020, China National Health Commission issued the Draft List of Second Batch of 19 Generic Medicines, encouraging pharmaceutical firms to develop and produce them. Medicines for chronic obstructive pulmonary disease and asthma are included in the list.
Dec 31, 2020
China's Social Medical Insurance to Cover More Drugs for Rare Diseases On Dec. 28, 2020, the National Healthcare Security Administration and Ministry of Human Resources and Social Security issued the 2020 Edition of the National Reimbursement Drug List (NRDL).
Dec 29, 2020
China to Exempt Import Tariffs on 61 Active Pharmaceutical Ingredients for Anticancer and Rare Disease Drugs China will apply interim import tax rates that are lower than most-favored-nation tariffs on 883 kinds of goods from Jan. 1, 2021, according to the 2021 Tariff Adjustment Plan issued by the Customs Tariff Commission of the State Council on Dec. 23, 2020.
Dec 22, 2020
China Requires Drug Market Authorization Holders to Submit Annual Report On Dec. 10, 2020, the National Medical Products Administration (NMPA) published the drafts of Administrative Provisions of Annual Drug Reports and Template for the Annual Drug Report, asking for public consultation before Dec. 22, 2020.
Dec 11, 2020
China Consults on the Draft of Good Pharmacovigilance Practices On Dec. 1, 2020, the National Medical Products Administration (NMPA) issued the draft of Good Pharmacovigilance Practices (GVP) for public comments. Stakeholders could submit feedback to NMPA before Dec. 18, 2020.
Dec 02, 2020
China Issued the 2020 Edition of Chinese Pharmacopoeia On Jul. 2, 2020, the National Medical Product Administration and the National Health Commission published the 2020 Edition of the Pharmacopoeia of the People’s Republic of China, which will come into force on Dec. 30, 2020.
Jul 03, 2020
- Monthly Recap: China Pharmaceutical Regulatory Updates | July 2021
- China Drug Evaluation Report 2020-Reform of Drug Review & Approval System
- Monthly Report: New Drug Approvals in China | Aug. 2021
- Monthly Recap: China Pharmaceutical Regulatory Updates | Aug. 2021
- China to Exempt Eligible Medical Devices and IVD Reagents from Clinical Evaluation or Trials